Drug search by name

Mitomycin Intravenous and Myelosuppression

Generic Name: mitomycin
Dosage Forms: n.a.
Other Brand Names: Mutamycin

Result of checking the interaction of drug Mitomycin Intravenous and disease Myelosuppression for safety when used together.

Check result:

Mitomycin Intravenous <> Myelosuppression

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Mitomycin induces cumulative, delayed myelosuppression. Neutropenia and thrombocytopenia can occur anytime within eight weeks after initiation of therapy. Anemia occurs less frequently. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended. Therapy with mitomycin should be withheld if white blood cell counts fall below 4000/mm3 and/or platelet counts fall below 100,000/mm3 and subsequent dosages modified based on the nadir of the previous dose.

References: